Beacon Pharmaceuticals: Plans to issue 48 million shares, raising net proceeds of approximately HK$780 million.

On the morning of August 7th, Boan Bio announced on the Hong Kong Stock Exchange that on August 6th, 2025, the company and the placing agents entered into a placing agreement. The total number of placing shares that may be sold under the placing matter is 48 million shares, equivalent to approximately 8.36% of the total number of issued shares as of the date of this announcement. The placing price is HK$16.42 per share, representing a discount of approximately 8.78% compared to the closing market price on the last trading day on the Stock Exchange. The net proceeds expected to be raised from the placing matter is approximately HK$780 million, with approximately 50% to be used for research and development, clinical trials, registration documents, and the manufacture of innovative candidate products; approximately 20% to be used for the commercialization of existing and upcoming products; and approximately 30% to be used for replenishing the company's operating funds and general business purposes.